NEW YORK

,

March 18, 2021

/PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST). Such investors are advised to contact

Robert S. Willoughby

at

[email protected]

or 888-476-6529, ext. 7980.

The investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On

September 25, 2020

, Aquestive announced receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) “regarding the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for management of seizure clusters.” Aquestive advised investors that “[i]n the CRL, the FDA cited that, in a study submitted by the Company with the NDA, certain weight groups showed a lower drug exposure level than desired. The Company intends to provide to the FDA additional information on PK modeling to demonstrate that dose adjustments will obtain the desired exposure levels.”

On this news, Aquestive’s stock price fell

$2.64

per share, or 34.69%, to close at

$4.97

per share on

September 28, 2020

.

The Pomerantz Firm, with offices in

New York

,

Chicago

,

Los Angeles

, and

Paris

is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late

Abraham L. Pomerantz

, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See

www.pomerantzlaw.com

.

CONTACT:

Robert S. Willoughby


Pomerantz LLP


[email protected]


888-476-6529 ext. 7980

View original content:

http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-aquestive-therapeutics-inc—aqst-301250716.html

SOURCE Pomerantz LLP